TUBB binds colchicine

Stable Identifier
R-HSA-9685830
Type
Reaction [binding]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Colchicine is an antimitotic agent used to treat gout and Behçet's disease (Cerquaglia et al. 2005, Saleh & Arayssi 2014, Angelidis et al. 2018). It works by decreasing inflammation. Colchicine primarily inhibits tubulin (TUBB) (Lu et al. 2012), preventing microtubule polymerisation and thereby disrupts inflammasome activation, microtubule-based inflammatory cell chemotaxis, generation of leukotrienes and cytokines, and phagocytosis.

The COLCORONA trial conducted by the Montreal Heart Institute (MHI) (https://clinicaltrials.gov/ct2/show/NCT04322682) showed that the use of colchicine was associated with statistically significant reductions in the risk of death or hospitalization in patients with Covid-19 compared to placebo. Colchinine showed efficacy in preventing the 'cytokine storm' and other complications associated with Covid-19.

Literature References
PubMed ID Title Journal Year
22814904 An overview of tubulin inhibitors that interact with the colchicine binding site

Lu, Y, Chen, J, Xiao, M, Li, W, Miller, DD

Pharm. Res. 2012
Participants
Participates
Authored
Reviewed
Created
Cite Us!